0.74Open0.74Pre Close0 Volume1 Open Interest2.50Strike Price0.00Turnover1695.22%IV265.28%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier13DDays to Expiry0.74Extrinsic Value100Contract SizeAmericanOptions Type0.9059Delta0.0579Gamma1.20Leverage Ratio-0.0192Theta0.0000Rho1.09Eff Leverage0.0003Vega
Karyopharm Therapeutics Stock Discussion
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics presented updated subgroup analyses from the SIENDO study at the 2024 ASCO Meeting, focusing on advanced or recurrent TP53 wild-type endometrial cancer. Key findings include a median progression-free survival (PFS) of 28.4 months fo...
No comment yet